Adipotide: Cutting the Blood Supply to White Fat
Last updated: March 2026
Adipotide (FTPP) targets the blood vessels of white fat tissue, inducing apoptosis in their endothelial cells and cutting off the tissue's blood supply. In obese rhesus monkeys, 28 days of treatment produced ~11% body weight loss (Barnhart et al. 2011, PMID 22072637). Kidney toxicity is the main safety concern, and no human efficacy results have been published.
Primate Study (28 days)
Rhesus Monkey Studies
No Human Results Published
How Adipotide Works
Adipotide uses a two-domain strategy: a targeting sequence that homes to white adipose tissue vasculature, and a proapoptotic sequence that destroys the endothelial cells of fat blood vessels. Cut off the blood supply — the fat cells die. This is fundamentally different from metabolic approaches.
The targeting domain of adipotide (sequence: CKGGRAKDC) binds to two receptors — annexin A2 (ANXA2) and prohibitin — on the luminal surface of white adipose tissue vasculature. The peptide reaches these receptors via systemic circulation and accumulates in white fat.
Once bound, the proapoptotic domain (D(KLAKLAK)2) disrupts mitochondrial membranes. This amphipathic peptide inserts into the inner mitochondrial membrane, dissipating the electrochemical gradient required for ATP synthesis. The result is rapid apoptosis of the endothelial cells lining the fat blood vessels. Without vascular supply, white fat cells undergo ischemic death.
In the Barnhart et al. (2011) rhesus monkey study, magnetic resonance imaging (MRI) and dual-energy x-ray absorptiometry (DXA) confirmed a marked reduction in white adipose tissue. The effect was not confined to fat: the same studies recorded kidney effects (see below).
Kidney toxicity was the primary side effect in treated monkeys — dose-dependent elevations in serum creatinine and histological evidence of kidney tubule damage. The study authors described these changes as relatively mild and reversible after dosing stopped. A safe therapeutic window for humans has not been established.
What the Primate Studies Show
All data from Barnhart et al., Science Translational Medicine, 2011 (PMID 22072637) — obese rhesus monkeys treated with adipotide vs. saline control over 28 days. No human clinical data has been published.
Observed Toxicity (Primate Data)
Safety data from primate studies only. Human incidence rates are unknown. Kidney toxicity is the primary safety concern.
Key Takeaways
- ~11% body weight loss in obese primates over 28 days, with marked white fat reduction on MRI and DXA
- Mechanism is unusual — targets the blood vessels of white fat directly
- Targets white fat vasculature via ANXA2/prohibitin binding
- Secondary improvement in insulin sensitivity observed
- No published human clinical trial data as of 2026
- Whether a safe human dose exists given kidney toxicity in primates
- Long-term effects of fat vasculature destruction on tissue architecture
- Whether weight loss is durable after treatment cessation
- Safety in humans is entirely unknown — this is strictly research-only
🛒 Recommended Products
General health and body-composition tracking products.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
This page is for educational and research purposes only. Adipotide (FTPP) is an experimental compound with no published human clinical trial results. It has demonstrated kidney toxicity in primate studies. It is not approved by the FDA or any regulatory agency. This is emphatically not medical advice. Do not use this compound — its safety profile in humans is entirely unknown.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.